Buy, Sell or Hold: 23andMe (ME-Q)

Home

Daily Stock Opinions and Ratings

23andMe (ME-Q)

NASDAQ:ME

0.52

0.09 (14.42%) 1d

Nervous markets await Nvidia

BUY ON WEAKNESS

He's shocked this is so low. Glaxo should buy them. At $2, the risk is priced in. Buy.

BUY

It's a genetic testing company with subscription services to let you know how your genes could effect your health. They went public last June, but has fallen since from $11 to $8. He doesn't understand why. Gene sequencing is the future of medicine and this company holds a treasure trove of data (kept private) that could be applied in medicine.

Showing 1 to 2 of 2 entries

23andMe(ME-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for 23andMe is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

23andMe(ME-Q) Frequently Asked Questions

What is 23andMe stock symbol?

23andMe is a American stock, trading under the symbol ME-Q on the NASDAQ (ME). It is usually referred to as NASDAQ:ME or ME-Q

Is 23andMe a buy or a sell?

In the last year, there was no coverage of 23andMe published on Stockchase.

Is 23andMe a good investment or a top pick?

23andMe was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for 23andMe.

Why is 23andMe stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is 23andMe worth watching?

0 stock analysts on Stockchase covered 23andMe In the last year. It is a trending stock that is worth watching.

What is 23andMe stock price?

On 2025-03-29, 23andMe (ME-Q) stock closed at a price of $0.5189.

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Teal Linde

Linde Equity Report

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Michael Hakes - CFA, MBA

Murray Wealth Group

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.